Clovoxamine kinetics in an early clinical trial

Harrell E. Hurst, David R. Jones, Jesse H. Wright, Charles H. Jarboe

Research output: Contribution to journalArticle

1 Scopus citations


Elimination kinetics of the new antidepressant clovoxamine were determined in a preliminary clinical trial in 10 depressed patients. When final oral doses of 50 mg clovoxamine fumarate were given, the mean peak steady-state plasma concentration was about 60 nglml after 3 hr. Clovoxamine elimination proceeded by an apparent single-phasic, first-order decline with a mean t 1 2 of 9.5 ± 2.8 hr. One subject had an unusually long t 1 2 (31.5 hr) and had correspondingly high clovoxamine plasma concentrations. The mean apparent volume of distribution (Vd) calculated from oral dosage was 19.5 ± 6 l/kg, but one atypical subject had an apparent Vd of 96 llkg. The mean apparent oral clearance was 25.5 ± 12.5 ml/min/kg. These parameters should be of assistance in planning dosage regimens and monitoring therapeutic blood levels according to kinetic principles. Atypical clovoxamine kinetics can be associated with abnormally high or low blood levels and could therefore lead to variability in clinical response.

Original languageEnglish (US)
Pages (from-to)266-271
Number of pages6
JournalClinical Pharmacology and Therapeutics
Issue number2
StatePublished - Aug 1983

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Clovoxamine kinetics in an early clinical trial'. Together they form a unique fingerprint.

  • Cite this

    Hurst, H. E., Jones, D. R., Wright, J. H., & Jarboe, C. H. (1983). Clovoxamine kinetics in an early clinical trial. Clinical Pharmacology and Therapeutics, 34(2), 266-271.